Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of LY3537031 in Participants With Hepatic Impairment
NCT07165002Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2025
- Primary completion
- Nov 2026
- Countries
- 3
01
Overview
Phase 1, open-label trial of LY3537031 (4 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve and Maximum Concentration. Started Oct 2025; status: recruiting.
02
Drugs
LY3537031
Beyond the preview
Go deeper on NCT07165002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07165002.